Polymorphisms in and are associated with the survival of triple-negative breast cancer patients treated with taxane-based adjuvant chemotherapy.

PURPOSE

Triple-negative breast cancer (TNBC) is more than a single disease. Identifying biomarkers to further subdivide TNBC patients with distinct outcome is of great importance. It has been reported that single-nucleotide polymorphisms (SNPs) in () or () are associated with the risk and survival of several cancers. But till now, there is no research about these polymorphisms in TNBC patients.

MATERIALS AND METHODS

In this study, we investigated the association between polymorphisms in or gene and prognosis of TNBC patients treated with taxane-based adjuvant chemotherapy. A total of 273 TNBC patients were enrolled. Haploview 4.2 software was used to identify Tag SNPs. Genotyping was conducted using the MassARRAY MALDI-TOF system.

RESULTS

We found that rs6099128 GG genotype carriers had significantly worse overall survival (OS) than TT+ TG genotype carriers ( = 0.003, HR = 12.499, 95% CI = 2.357-66.298). rs11651993 TT genotype carriers had better disease-free survival (DFS) than TC + CC genotype carriers ( = 0.018, HR = 1.876, 95% CI = 1.116-3.154). rs2289590 CC genotype carriers had worse DFS than CA + AA genotype carriers ( = 0.021, HR = 0.536, 95% CI = 0.315-0.912). After subgroup analysis, rs11651993 TC + CC genotype predicted worse DFS in subgroups of age ≤ 50, post-menopausal, grade unknown (UK), tumor size >2 cm, and lymph node negative. Rs2289590 CA + AA genotype could predict favorable DFS in pre-menopausal, grade 3 and lymph node-positive patients.

CONCLUSION

We first demonstrated that polymorphisms in or gene might predict the OS or DFS of TNBC patients treated with taxane-based adjuvant chemotherapy.